November 2, 2026 5:13 PM
Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target
The recent failure of a Novartis Sexperimental heart drug in a large trial raised questions among cardiologists and investors about the widely held idea that reducing levels of a genetically set cholesterol carrier called lipoprotein(a) can improve heart health. Doctors say the upcoming release of trial details will shed light on whether drugs that target the blood particle, commonly referred to as Lp(a), or "LP little a," might be the next big breakthrough in heart disease prevention, or wheth...